| 1 |
Siu LK, Yeh KM, Lin JC, et al. Klebsiella pneumoniae liver abscess: a new invasive syndrome[J]. Lancet Infect Dis, 2012，12(11): 881-887.
|
| 2 |
Holt KE, Wertheim H, Zadoks RN, et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health[J]. Proc Natl Acad Sci U S A, 2015，112(27): E3574-E3581.
|
| 3 |
Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria[J]. Lancet Infect Dis, 2009，9(4): 228-236.
|
| 4 |
Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern[J]. Lancet Infect Dis, 2008，8(3): 159-166.
|
| 5 |
Wang Y, Lei H, Zhang Y, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae bloodstream infections after renal transplantation from donation after cardiac death in a Chinese hospital: a case series analysis[J]. Antimicrob Resist Infect Control, 2018，7: 66.
|
| 6 |
Akova M, Daikos GL, Tzouvelekis L, et al. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria[J]. Clin Microbiol Infect, 2012，18(5): 439-448.
|
| 7 |
Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae[J]. Nat Rev Microbiol, 2020，18(6): 344-359.
|
| 8 |
李文磊，武聚山，贾哲，等. 肝移植术后耐碳青霉烯肺炎克雷伯菌感染危险因素分析[J/CD]．中华移植杂志：电子版，2021，15(6): 347-352.
|
| 9 |
Liang H, Zhang P, Yu B, et al. Machine perfusion combined with antibiotics prevents donor-derived infections caused by multidrug-resistant bacteria[J]. Am J Transplant, 2022，22(7)：1791-1803.
|
| 10 |
Wang ZQ, Guo ZL, Feng H, et al. Treatment of donor-derived carbapenem-resistant Klebsiella pneumoniae infection after renal transplantation with tigecycline and extended-infusion meropenem[J]. Curr Med Sci, 2021，41(4)：770-776.
|
| 11 |
Okon E, Engell C, van Manen R, et al. Tigecycline-related pancreatitis: a review of spontaneous adverse event reports[J]. Pharmacotherapy, 2013，33(1)：63-68.
|
| 12 |
Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems[J]. Infection, 2020，48(6): 835-851.
|
| 13 |
Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms[J]. Antimicrob Agents Chemother, 2017，61(2)：e01964-e01966.
|
| 14 |
吴佳晋，李大伟，张明，等. 肾移植术后供肾来源耐碳青霉烯类肺炎克雷伯菌感染九例诊疗经验[J]. 中华器官移植杂志，2019，40(6)：334-338.
|
| 15 |
Soriano A, Carmeli Y, Omrani AS, et al. Ceftazidime-avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review[J]. Infect Dis Ther, 2021，10(4): 1989-2034.
|
| 16 |
马红叶，刘哲，张蕾，等. 医院2014—2020年肺炎克雷伯菌临床分布及耐药性研究[J]. 中国医药，2022，17(1)：88-92.
|